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Introduction
It has been reported that estrogen exposure is one of
the factors leading to the development of prolactino-
ma, a tumor of the pituitary [1]. Experimental estrogen
administration can induce prolactinoma in mice and
rats, which is characterized by cellular hyperprolifera-
tion and angiogenesis, thus providing a means for
investigating the mechanisms of pituitary tumorigene-
sis and effective therapeutic methods against it [2-4].
Melatonin, a neuroendocrine hormone derived from
5-hydroxytryptamine (5-HT) and initially synthesized
in the pineal body, is widely distributed in a variety of
organs and tissues. Wu et al. [5] demonstrated strong
expression of melatonin receptors (MT) in several cere-
bral nuclei and weak expression of the receptor MT1,
through which melatonin might exert its physiological
functions and pharmaceutical effects, in both the ante-
rior pituitary and the posterior pituitary glands. In addi-
tion, melatonin can protect neurons, enhance immune
function, delay senescence, and regulate cell division
[6,7]. The antiproliferative effects of melatonin were
also observed in multiple carcinoma cell lines of human
and mouse, as well as in diethylstilbestrol (DES)-
induced prolactinoma [8]. Recent investigations show
that melatonin suppresses the expression of estrogen
receptor (ER), inhibits ER binding to the estrogen
response element (ERE), reduces mutations in the
estrogen enhancer, and induces apoptosis of prolactin-
oma cells, leading to reductions in tumor volume [9-
11]. However, the molecular mechanisms of melatonin
treatment remain unclear.
Angiogenesis is a typical characteristic of pituitary
tumors and is a pivotal event in tumor invasion
[12,13]. The roles of VEGF, MMP-1, and AQP-1 have
been established in angiogenesis, suggesting roles in
tumor behavior [14-16]. Lissoni et al. [17] evaluated
the effect of melatonin on senior cancer patients, dis-
covering that control of tumor growth by melatonin
was related to reduced serum VEGF concentrations,
which suggested that melatonin functions as a natural
anti-angiogenesis agent to inhibit tumor growth. How-
ever, we are not aware of any prior reports on the effect
of DES on angiogenesis in pituitary tumors.
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Abstract: We studied the anti-tumorigenic effect of melatonin in diethylstilbestrol (DES)-treated anterior pituitaries in rats.
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treated rats co-administrated with melatonin beginning at week 13. At the end of 16 weeks, rats were weighed and decapi-
tated for morphological studies, including an H+E staining-based score evaluation in regard to cell proliferation, angiogen-
esis, immunostaining for VEGF, MMP-9, and AQP-1, and electron microscopy. Compared with vehicle, long-term treatment
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1 expression. In rats cotreated with melatonin, the RER loosened and accumulated more secretion granules. We thus con-
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In the present study, we investigated the effect of
melatonin on DES-induced expression of VEGF,
MMP-9, and AQP-1 and its possible effect on the
ultrastructure of the anterior pituitary. Compared with
rats without melatonin treatment, rats concurrently
receiving melatonin and DES demonstrated signifi-
cantly reduced expression of VEGF and MMQ-9,
accompanied by diminished ultrastructural deteriora-
tion of the pituitary tissue. Our findings suggest bene-
ficial effects of melatonin in estrogen-related pituitary
malfunction. 
Materials and methods
Animals and materials. Animal manipulation was approved by
the Animal Use Committee of Beijing Neurosurgical Institute. A
total of 21 female Wistar rats, 3 weeks old, and weighing 70-80 g
were used. All animals were housed with free access to tap water
and standard pellet food. They were kept at a controlled tempera-
ture (24±1°C) and humidity (55±5%), and a 12-hour day-night
cycle (10 a.m.-10 p.m.) was maintained. Rats were randomly
divided into 3 groups of 7, with each group receiving a different
treatment regimen: the vehicle control group, in which rats were
intraperitoneally administrated with sunflower seed oil (1 mL/kg,
twice a week) for 16 weeks; the DES group, which received DES
(5 mg/kg, twice a week) for 16 weeks; and the DES + melatonin
group, in which DES was administered for 16 weeks at the same
dose as in the DES group, with melatonin (1 mg/day) co-adminis-
tered at 5 p.m. each day from weeks 13 to 16. Rats in both vehicle
and DES groups received the same dose of vehicle in place of
melatonin, while the DES + melatonin group received melatonin.
DES and melatonin were purchased from Sigma Chemical Co.
(St Louis, MO, USA). Anti-VEGF antibodies were purchased from
Boster Biotech (Wuhan, China). MMP-9 and prolactin (PRL) anti-
bodies were purchased from Dako (Denmark). AQP-1 antibody
was purchased from Chemicon (Temecula, CA, USA). The DES
injection was prepared by dissolving DES powder in sunflower
seed oil to obtain a final concentration of 5 mg/mL.
Morphological score of anterior pituitary gland. After 16
weeks, rodents were anesthetized with chloroaldehyde, 10%
hydration (300 mg/kg) and perfused intracardially with a 40g/L
solution of paraformaldehyde in PBS (0.01M, pH 7.4). Tissues
were then embedded in paraffin, sectioned at 4 µm for H+E stain-
ing, and observed immunohistochemically. An evaluation score
system based on H+E staining was employed to compare the
changes in the anterior pituitary gland between each group.
Immunohistochemistry. After deparaffinization, sections were
rehydrated through a graded series of ethanol to phosphate buffer.
For antigen retrieval, the sections were incubated in 3% H2O2 to
clear endogenous peroxidase and were then saturated with 10%
normal goat serum for 10 minutes. Afterwards, sections were indi-
vidually incubated with anti-VEGF, -MMP-9, or -AQP-1 antibody
(1:50 dilution) at 4°C overnight. The antigen-antibody complexes
were visualized using the avidin-biotin-peroxidase complex (ABC)
method. Counterstaining was done with Meyer's hematoxylin.
Table 1 depicts the H+E scoring system used.
Transmission electron microscopy. One rat in each group was
randomly selected for transmission electron microscopic investiga-
tion. For electron microscopy, pituitary tissues were fixed in 2%
glutaraldehyde in 0.1 M PBS (pH 7.4) and then subjected to post-
fixation in 2% osmium tetroxide. Tissues were embedded in
Araldite, and the ultra-thin sections were examined under a Philips
EM208 electron microscope.
Ethical issues. The study was monitored by the Bioethical Com-
mittee of Beijing Tiantan Hospital, Capital Medical University,
China. The number of the license for animal use is SYXK (Beijing)
2008-005.
Statistical analysis. Results were expressed as mean ± standard
deviation (SD), and one-way ANOVA analysis was used to com-
pare differences in body weight and H+E score, with post-hoc
testing by Bonferroni test. Frequency distribution was applied to
test the normal distribution of data in each group using Skew-
ness method. P-values of less than 0.05 were considered signifi-
cant. 
Results
Physical and histological changes induced
by DES and melatonin
Fur loss and weight loss are the initial superficial
effects of intraperitoneal injection of DES in rats.
Compared with continuously DES-treated rats, mela-
tonin treatment appeared to reduce fur loss. The body
weights of rats in the vehicle control group, the DES
group, and the DES + melatonin group were
282.9±35.6 g, 239.9±20.7 g, and 248.7±17.4 g, respec-
tively. The frequency of values in each group was dis-
tributed in a normal mode. Compared with controls,
continuous treatment of DES without melatonin sig-
nificantly reduced body weight, which was mitigated
by coadministration of melatonin, although no signifi-
cance was observed.
In six out of seven vehicle-treated rats, pituitary tis-
sues showed no apparent abnormalities or gland cavi-
ty narrowing, and the pituitary cells were arranged
normally. One rat showed self-developed pituitary
hyperproliferation. By contrast, pituitary tissues in rats
receiving continuous administration of DES showed a
disappearance of the gland cavity, with subsequent
occupation by proliferated cells. Co-administration of
melatonin reduced structural abnormalities, with
increased gland cavity volume compared with the DES
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Table 1. Score based on H+E staining.
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group, possibly attributed to the sharp withdrawal of
proliferated cells. 
The H+E staining-based evaluation scores in the
vehicle, DES, and DES + melatonin groups were
1.42±1.13, 4.57±0.98, and 2.00±0.63, respectively,
and frequency distribution of values in each group
were in agreement with normal distribution. Long-
term treatment of DES significantly increased the H+E
score, which was reduced by subcutaneous injection of
melatonin (p<0.01 vs. DES group). In the sole pituitary
with spontaneous tumor-like changes, the tumor-like
cells were closely packed with similar cytoplasmic and
nuclear volumes, suggesting that they were from the
same origin. 
Effects of melatonin on VEGF, MMP-9,
and AQP-1
In the vehicle-treated pituitary tissues, VEGF was
selectively expressed in pituitary cells surrounding
blood vessels. By contrast, administration of DES led
to extensive expression of VEGF in the cytoplasm of
pituitary cells, accompanied by angiogenesis, which
was reduced by melatonin at a dose of 1 mg/day for 4
weeks (Fig. 1).
No apparent expression of MMP-9 was observed in
vehicle-treated rats, whereas administration of DES
produced diffuse expression of MMP-9. Co-adminis-
tration of melatonin abolished MMP-9 expression in
the pituitary (Fig. 1). At week 16, expression of AQP-
1 was increased in the endothelial cells of the pituitary
glands of rats receiving DES, which could not be
altered by melatonin administration (Fig. 1). 
Changes in ultrastructure
We previously reported in the DES-treated pituitary,
electron microscopic investigation revealed well-
developed rough endoplasmic reticulum (RER) and
faulty exocytosis in some cells, indicating the devel-
Fig. 1. Immunohistochemical stain-
ing of female Wistar rat anterior
pituitary gland for expression of
PRL, VEGF, MMP-9, and AQP-1.
V-vehicle control rats, DES-diehyl-
stilbestrol treated rats, DES+M-
diehylstilbestrol treated rats coad-
ministrated with melatonin. scale
bars=30µm.
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opment of prolactinoma [16]. Here, we also observed
the accumulation of secretion granules approaching
the blood vessels in the DES treated rat pituitary gland
(Fig. 2A). In pituitary tissues of rats co-treated with
melatonin, many premature, abnormally enlarged,
medium-density hormone containing granules were
observed in loosened endoplasmic reticulum, with an
average diameter of 300 nm (Fig. 2B), suggesting
melatonin may function by inhibiting the granule
extrusion.
Discussion
Prolactinoma is a multi-factorial disease. Although
dopamine agonists, including bromocriptine,
quinagolide, and lisuride, have proved to be effective in
most patients suffering from prolactinoma, there are still
many patients who show no response to these drugs or
who develop resistance to them [18]. In this investiga-
tion, rats were subjected to DES administration with or
without concurrent melatonin treatment, after which
immunohistochemistry and electron microscopy were
undertaken to investigate the effects of melatonin on the
expression of VEGF, MMP-9, and AQP-1, as well as its
effect on the ultrastructure of pituitary tissues. Our
results demonstrate the ability of melatonin to counter-
act DES-induced upregulation of VEGF and MMP-9
expression and its ability to improve the ultrastructure
of DES-treated pituitary tissue.
Although investigations have demonstrated that the
pineal body influences PRL release, little is known
about the effects of the pineal body on hyperprolactine-
mic diseases, and pineal body activity is usually exclud-
ed from clinical investigations of pituitary tissues. Liss-
noi et al. [19] investigated the effects of melatonin
injection on serum PRL in 19 patients with hyperpro-
lactinemia. They found that intramuscular injection of
melatonin led to the reduction of serum PRL in 3 out of
8 patients with congenital hyperprolacthemia. Subse-
quent investigation [17] showed that the serum mela-
tonin level in these patients was significantly lower than
in normal controls. Additionally, patients with
acromegaly and pituitary tumors showed no response in
terms of serum growth hormone or prolactin to acute
administration of melatonin. Thus, the effects of long-
term melatonin treatment need further elucidation.
Xu et al. [9,20] used controllable pumps containing
estradiol to induce the development of prolactinoma in
rats, which received melatonin treatment from 7 days
before implantation to 90 days after implantation. The
results demonstrated that melatonin could effectively
abolish the growth of prolactinoma by inhibiting PRL
and ER expression and could partially prevent the
binding of ER to ERE.
Melatonin, at an appropriate dose, can also reduce
mutations in the PRL gene enhancer, preventing over-
expression of PRL and resulting in the decreased
growth of prolactinomas [10]. Further investigations
demonstrated that melatonin can increase the activity
of caspase-3, increasing the expression of Bcl-2 and
facilitating decreases in mitochondrial membrane
potential, which promote apoptosis and reduce tumor
mass [11,21]. Notably, melatonin treatment was initi-
ated before DES induction in previous studies. In con-
trast to this preventive mode of treatment, we adminis-
tered melatonin after 12 weeks of DES pre-treatment.
Co-administration of melatonin with DES could
promote the re-emergence of the adenoid cavity, espe-
cially in the areas approaching the margin of the ante-
rior pituitary gland. This may be caused by the rapid
retreat of proliferative cells, allowing greater blood
flow and thus leaving a larger cavity. It can be specu-
lated that further increases in blood flow might rupture
the vessels. Therefore, an effective dose of melatonin
will need to be determined to optimize vascular stabil-
ity during melatonin treatment.
Electron microscopy is a sensitive and reliable
method for observing the earliest ultrastructural
changes related to the development and treatment of a
pituitary tumor. Using immune electron microscopy,
Fig. 2. Electron microscopy on pitu-
itary tissues. Accumulated secretion
granules for extrusion into the blood
vessels were observed in the DES
treated rat pituitary gland (A),
whereas in the DES treated rat pitu-
itary co-administrated with mela-
tonin, most of these granules were
seen in the loosened structure of the
rough endoplasmic reticulum (B).
Osamura et al. [22] found that PRL was located in the
well-developed, double-layered, concentric rough
endoplasmic reticulum. Bromocriptine caused the
cytoplasm to shrink and unsecreted PRL granules to
aggregate, with the abrogation of exocytosis. Eljarmak
et al. [23] found that continuous bromocriptine admin-
istration reduced the volumes of the cell, the rough
endoplasmic reticulum, and the Golgi complex. The
ultrastructural improvements conferred by melatonin
provided strong evidence for its efficacy as a thera-
peutic. Melatonin has been shown to reduce tumor size
and serum PRL concentration without the misplaced
exocytosis or disruption of RER. 
In the present study, administration of melatonin
for 4 weeks caused the accumulation of large PRL
secretory granules in loosened RER, suggesting mela-
tonin may inhibit the exocytosis of PRL-containing
granules and reduce the expression of PRL through
negative feedback. The structural improvements to the
concentric RER support this.
The anti-cancer activity of melatonin, primarily a
product of the pineal body and a natural tumor
inhibitor, has been related to its immune-regulatory,
anti-proliferation, and anti-oxidant effects. Angiogene-
sis is a key step in the development and metastasis of
most tumors, including pituitary tumors. However,
compelling data concerning melatonin in angiogenesis
are not yet available. Soybir et al. [24] found that
melatonin could function in angiogenesis and wound
repair, which was related to the regulatory effects of
melatonin on monocytes, cytokines, and fibroblastoma
cells. Cui et al. [25] found that melatonin could inhib-
it the growth of cultured umbilical vein endothelial
cells, inducing apoptosis by regulating the cell size,
which involved p53 and Bax/Bcl expression changes.
EGF and VEGF are involved in angiogenesis, stimu-
lating cellular proliferation, promoting vasculariza-
tion, and sustaining the integrity of vessels, meaning
these proteins play an important role in tumor metasta-
sis [26-28]. The present study demonstrated DES-
induced upregulation of VEGF and MMP-9, confirm-
ing a role for estrogen in angiogenesis in the rat ante-
rior pituitary. Melatonin has been reported to down-
regulate MMP-9 expression and activity in several
pathological states in rodents, such as reperfusion-
induced hemorrhage following transient focal cerebral
ischemia and spinal cord injury [29-31]. The inhibito-
ry effects of melatonin may be associated with reduced
expression of TNF-α and elevated expression of tissue
inhibitor of metalloproteinase (TIMP)-1 [30,32]. 
Melatonin reduced the expression of both VEGF and
MMP-9, accompanied by an improvement in H+E score,
suggesting these molecules are targets of melatonin in
the treatment of estrogen-induced pituitary malfunction.
Further study is needed to determine why AQP-1 was
upregulated by DES and not suppressed by melatonin. 
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